Business Wire

HCL Group and UpLink Announce Winners of ‘Tackling Water Pollution Challenge’ Under the Aquapreneur Innovation Initiative

21.1.2025 17:18:00 EET | Business Wire | Press release

Share

HCL Group, a leading global conglomerate, and UpLink, the World Economic Forum’s early-stage innovation initiative, have announced the winners of the 'Tackling Water Pollution Challenge,’ the third in a series of five challenges under the five-year, CHF 15 million Aquapreneur Innovation Initiative launched by HCL Group. The announcement marks a significant step in the ongoing mission to address global water challenges through groundbreaking innovation and entrepreneurship.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121986084/en/

Roshni Nadar Malhotra, Chairperson of HCL Group, announces the winners of ‘Tackling Water Pollution Challenge’ under the Aquapreneur Innovation Initiative in Davos. (Photo: Business Wire)

After evaluating over 270 submissions from around 60 nations, 10 Aquapreneurs from 9 countries were chosen for their innovative solutions in the freshwater sector. This year’s winners, termed ‘UpLink Top Innovators and Aquapreneurs’, reflect a diverse set of expertise demonstrating the transformative potential of innovation in tackling water pollution worldwide. The winners will share financial award from a pool of CHF 1.75 million, enabling them to scale their initiatives and amplify their impact. In addition to funding, the winners will also gain access to exclusive resources, mentorship, and global networks provided by HCL Group and UpLink.

The Tackling Water Pollution Challenge was dedicated to addressing freshwater issues worldwide, with special focus on combating water pollution. Solutions presented by winners included cutting-edge advancements in filtration systems, wastewater treatment, industrial water reuse, and water quality monitoring technologies.

Highlighting the role of Aquapreneur Innovation Initiative in combating challenges related to freshwater, Roshni Nadar Malhotra,Chairperson of HCL Group, said: “Water scarcity and pollution are existential threats to humanity and biodiversity. The Aquapreneur Innovation Initiative launched a couple of years ago aims to discover and support the most innovative start-ups and scale-ups tackling the world’s most pressing water issues. The 20 pioneering start-ups, winners of the previous two years, have collectively gone on to achieve immense success. In 2024 alone, they helped save over 12 billion litres of water, equivalent to Switzerland’s entire water footprint each year. They also treated 3 billion litres of wastewater. The Grant provided by HCL enabled them to expand to new markets, deploy pilot projects, increase customer count, and scale-up production and operations. These 20 start-ups have raised US$70 million in funding since joining the Initiative. So, congratulations to all ten of this year’s winners. I’m already looking forward to returning to Davos next year to share their successes!”

Added Olivier Schwab, Managing Director of the World Economic Forum, “As water challenges grow more urgent, HCL Group and UpLink’s continued commitment underscores the need for collaborative innovation to safeguard freshwater ecosystems. The initiative is not just driving immediate solutions, investment and multistakeholder partnerships —it is paving the way for a sustainable future where clean, accessible water is a reality for all. By supporting bold, scalable solutions, we are making a critical contribution to addressing one of the most significant global challenges of our time. The collaboration between HCL Group and UpLink continues to set a global benchmark for how innovation can drive large-scale, lasting change.”

Water pollution is a global challenge, with about 80% of the world's untreated wastewater being released into rivers, lakes, and oceans. This leads to 485,000 premature deaths every year worldwide and costs the global economy $260 billion annually. The challenge of water pollution intensifies as countries industrialize, with chemical contamination of freshwater sources being prominent across industrial economies. This includes the rise of microplastics and PFAS (Per- and polyfluorinated alkyl substances), also known as the Forever Chemicals in water supplies, risking public health.

The 2025 Tackling Water Pollution Challenge Winners

  • Aquagga, United States of America, focuses on innovative PFAS destruction using its Hydrothermal Alkaline Treatment (HALT) technology for environmental remediation and wastewater treatment.
  • Digital Paani, India, focuses on enhancing operational excellence in water treatment, addressing water scarcity and pollution through scalable solutions in under-resourced areas.
  • Fluidion, France, advances water intelligence with innovative sampling solutions that monitor pollution and water quality across urban, natural, and industrial environments.
  • FREDsense, Canada, provides in-field lab-based water quality testing solutions, empowering utilities and environmental consultants with real-time, accurate data for effective water management.
  • Fungi Life, Colombia, uses fungal biotechnology to create sustainable ingredients, aiming for net-zero emissions by revalorizing agro-industrial waste for environmental sustainability.
  • Mimbly, Sweden, optimizes water resources in the laundry industry through innovative recycling and filtration solutions, promoting sustainability with advanced water-saving technologies.
  • Oxyle, Switzerland, offers an economical, sustainable solution to PFAS contamination by completely eliminating PFAS from water, empowering industrial and environmental remediation companies to tackle contamination effectively.
  • SENTRY, Canada, is a biological activity and water quality monitoring platform that uses unique bio-electrode sensor technology for real-time microbial performance monitoring in wastewater treatment systems.
  • Syrinx, Australia, offers innovative water treatment solutions with its nature-based 'Wetland-in-a-Box'® (EnPhytoBox), addressing water pollution and boosting climate resilience, especially in agriculture.
  • WASE, United Kingdom, treats industrial wastewater onsite, helping customers comply with regulations, maximize bioenergy generation, and decarbonize thermal energy demands through sustainable, economically viable solutions.

In addition to the financial awards, the winners will have the opportunity to participate in events and projects led by the World Economic Forum and its partners. These opportunities will provide invaluable support to scale their ventures, ensuring sustainable and impactful solutions for water challenges.

Since its inception, the Aquapreneur Innovation Initiative has made notable progress in addressing global freshwater challenges. This funding has enabled winners to innovate, scale production, and expand into new markets. The initiative has also driven progress in water conservation, wastewater treatment, greenhouse gas emission reductions, and job creation. To date, top innovators have cumulatively raised over $70 million in funding to scale their innovations.

HCL Group and UpLink’s ongoing collaboration underscores their shared commitment to sustainability and innovation, paving the way for a future where freshwater resources are managed responsibly and effectively.

Notes to the editor

About UpLink

UpLink is the World Economic Forum’s early-stage innovation initiative that builds ecosystems that enable purpose-driven, early-stage entrepreneurs to scale their business for the markets and economies that are essential for a net-zero, nature-positive, equitable future.

Sourcing innovations through a competition framework known as innovation challenges, UpLink has run more than 50 challenges to date and selected over 500 early-stage entrepreneurs with innovative solutions across critical SDG areas including freshwater, health, food, ocean, plastics, education, climate and more.

For more information, visit https://uplink.weforum.org

About HCL Group:

Founded in 1976 as one of India’s original IT garage start-ups, HCL Group is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978 well before its global peers. Today, the HCL Group has a presence across varied sectors that include technology, healthcare and talent management solutions and comprises three companies – HCL Infosystems, HCLTech and HCL Healthcare. The enterprise generates annual revenues of over US$13.8 billion with 220,000 employees operating across 60 countries. For further information, visit www.hcl.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250121986084/en/

Contacts

For further information, please contact:


Shruti Saxena: shruti-saxena@hcl.com (9654356487)
Alisha Bisherwal: Alisha.a@hcl.com (8447821231)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye